Acute coronary syndrome: how to reduce the residual inflammatory risk?
Inflammatory mediators play an important role in the pathogenesis of acute coronary syndrome (ACS). The results of experimental and randomized clinical trials on the role of various inflammation inhibitors in the treatment of coronary artery disease (CAD), in particular CANTOS and COLCOT, mark a new...
Saved in:
Main Author: | V. I. Shalnev |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«FIRMA «SILICEA» LLC
2020-03-01
|
Series: | Российский кардиологический журнал |
Subjects: | |
Online Access: | https://russjcardiol.elpub.ru/jour/article/view/3720 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Statins in acute coronary syndrome
by: O. M. Drapkina
Published: (2009-10-01) -
STATINS IN ACUTE CORONARY SYNDROMES
by: A. L. Alyavi, et al.
Published: (2019-03-01) -
Aggressive statin therapy in acute coronary syndrome: therapeutic potential of atorvastatin in the daily dose of 80 mg
by: A. N. Britov
Published: (2009-12-01) -
Short Term Comparison Between Safety and Efficacy of Rosuvastatin 40 mg and Atorvastatin 80 mg in Patients with Acute Coronary Syndrome
by: Sh. A. Mostafa, et al.
Published: (2018-11-01) -
RISK OF RECURRENT THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME AND HIGH PLASMA LEVELS OF D-DIMER
by: A. V. Panina, et al.
Published: (2013-08-01)